European Lung Cancer Congress 2024

Immune checkpoint inhibitors such as durvalumab plus chemotherapy are first-line treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC), yet durable clinical benefits are not seen for many. As low-dose radiation therapy (LDRT) could induce a priming effect of the immune system, Yan Zhang (West China Medical Center of Sichuan University, Chengdu, China) and colleagues investigated adding LDRT (15 Gy in five daily fractions) to durvalumab plus etoposide–platinum chemotherapy in a single-arm, phase 2 trial (LEAD) of 30 patients with ES-SCLC in China.